Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PLSE 
Pulse Biosciences Inc (PLSE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PLSE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -3.33% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) - | Beta 1.63 | 52 Weeks Range 10.52 - 25.00 | Updated Date 06/29/2025 |
52 Weeks Range 10.52 - 25.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.99 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.61% | Return on Equity (TTM) -77.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 903787838 | Price to Sales(TTM) 60.23 |
Enterprise Value 903787838 | Price to Sales(TTM) 60.23 | ||
Enterprise Value to Revenue 64.63 | Enterprise Value to EBITDA -1.81 | Shares Outstanding 67273904 | Shares Floating 17434021 |
Shares Outstanding 67273904 | Shares Floating 17434021 | ||
Percent Insiders 74 | Percent Institutions 8.64 |
Upturn AI SWOT
Pulse Biosciences Inc
Company Overview
History and Background
Pulse Biosciences, Inc. was founded in 2009. It focuses on developing and commercializing its proprietary Nano-Pulse Stimulation (NPS) technology. It has evolved from research and development to commercializing its CellFX system.
Core Business Areas
- Dermatology: Pulse Biosciences primarily focuses on dermatological applications of its NPS technology, specifically for the removal of skin lesions.
- Other: The company explores other applications of its NPS technology in aesthetics and potentially other medical fields.
Leadership and Structure
The leadership team includes a CEO, CFO, and various VPs overseeing different departments. The company has a board of directors providing oversight.
Top Products and Market Share
Key Offerings
- CellFX System: The CellFX System is Pulse Biosciences' primary product, utilizing NPS technology for dermatologic procedures. Market share data is difficult to ascertain due to the emerging nature of the technology and competition from lasers, cryotherapy, electrosurgery, and chemical peels. Revenue figures are available in the company's financial reports. Competitors include companies that produce lasers, cryotherapy, electrosurgery, and chemical peels.
Market Dynamics
Industry Overview
The dermatology market is characterized by continuous innovation with the introduction of new technologies and procedures for skin treatments. The market is competitive and driven by consumer demand for aesthetic improvements and medical treatments for skin conditions.
Positioning
Pulse Biosciences is positioning itself as a leader in the use of NPS technology for dermatologic applications. Its competitive advantage lies in the non-thermal nature of its NPS technology, which may result in better cosmetic outcomes compared to traditional methods.
Total Addressable Market (TAM)
The total addressable market for dermatological treatments is significant, with estimates varying widely. The CellFX System targets a portion of this market. Precise TAM is hard to find. NPS targets skin treatments which is within the dermatological TAM.
Upturn SWOT Analysis
Strengths
- Proprietary NPS technology
- Potential for improved cosmetic outcomes
- Focus on dermatology
Weaknesses
- Limited commercial adoption to date
- Dependence on a single product
- High operating expenses
- History of losses
Opportunities
- Expansion into new dermatological applications
- Partnerships with dermatologists and medical practices
- International market expansion
- Expansion of NPS into other markets
Threats
- Competition from established dermatological technologies
- Regulatory hurdles
- Slow adoption by dermatologists
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- COHR
- CUTR
- ALGN
Competitive Landscape
Pulse Biosciences' NPS technology offers a potential advantage over traditional methods, but it faces competition from established players with broader product portfolios and larger customer bases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the early stage of commercialization.
Future Projections: Future growth depends on successful commercialization of the CellFX System and expansion into new applications. Analyst estimates can vary widely.
Recent Initiatives: Recent initiatives include expanding the sales and marketing efforts for the CellFX System and pursuing regulatory approvals in new markets.
Summary
Pulse Biosciences is a company with innovative technology in the dermatology space but faces significant challenges in commercializing its CellFX system. It is highly dependent on the successful adoption of NPS technology. The company's history of losses and high operating expenses are concerning. Pulse Biosciences must focus on driving revenue growth and managing costs effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports (FactSet, Yahoo Finance, etc.)
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is approximate and may vary depending on the source. Financial data should be verified with the company's official SEC filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pulse Biosciences Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2016-05-18 | President, CEO, Principal Executive Officer, Principal Financial Officer & Co-Chairman of the Board Mr. Paul Arthur LaViolette | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 75 | Website https://www.pulsebiosciences.com |
Full time employees 75 | Website https://www.pulsebiosciences.com | ||
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.